Patsnap

🧭 AI maps the landscape. Humans choose the destination. Teams that combine both move faster. 🔗 Stop asking the wrong questions: https://bit.ly/47MZZbE #AITools #InnovationStrategy #ProductDevelopment #TechInsights

We’re excited to share that we’ll be attending INTA 2026 in London! 🎡 If you’re heading to the event, come meet the team at booth 331. Billy Hulks, Yen Cortez, Mariana Morais, Hugo Mallinckrodt, and Stanley Humphry will be there to show you how Patsnap is helping IP and innovation teams turn complex patent data into clear, actionable insights. From portfolio strategy to competitive intelligence, we’re working with organizations to make faster, more confident decisions in an increasingly dynamic IP landscape. Planning to attend? Drop a comment or message us, we’d love to connect and say hello in person! #INTA2026 #INTAAnnualMeeting #London #IP #Innovation #Patsnap

Patsnap is excited to announce our partnership with AEVO, the largest innovation and strategy management platform in Latin America. With this collaboration, we have embedded our Find Solutions AI agent directly into AEVO Innovate. This integration allows their enterprise clients to transition seamlessly from submitting an idea to receiving a structured, evidence-based R&D execution plan without leaving their workflow. Find Solutions leverages billions of data points from global patents and scientific publications to identify viable technical approaches, map trade-offs, and expedite the journey from ideation to execution. This development is significant because sophisticated R&D intelligence has traditionally been confined to large, well-resourced teams equipped with specialised tools and expertise. We aim to democratize access to this intelligence, empowering every innovation team by embedding it into the platforms they already utilise. For platform builders or product teams, this partnership exemplifies the potential of integrating domain-specific AI agents into existing workflows. If you are developing tools for R&D, engineering, or innovation teams and are interested in exploring the possibilities with PatSnap's open platform capabilities, we would be eager to connect. Congratulations to Luis Carvalho and the entire AEVO team on this collaboration - we look forward to working with you. 🔗 https://lnkd.in/eeNPUhm7

We're thrilled to announce our partnership with AEVO! 🌎 PatSnap's Find Solutions AI agent is now embedded directly inside AEVO Innovate, the leading innovation management platform for enterprise teams across Latin America. R&D teams have always had great ideas. What's been missing is a fast, structured way to validate them against prior art, map technical trade-offs, and build a clear path to execution. That's exactly what Find Solutions brings, now living natively inside the platform teams already use every day. Latin America's innovation market is one of the fastest-growing in the world, and this is our first integration partnership in the region. We couldn't be more excited to be part of that momentum alongside the AEVO team. 🙌 Read the full story: https://bit.ly/4e8PyDh Luis Carvalho #PatSnap #AEVO #LatinAmerica #Innovation #RD #AIAgents #IPIntelligence

Rory McIlroy just won back-to-back Masters. While the world watched the swing, we saw something else. Every club in that bag, every dimple on that ball, every groove on that clubface is protected IP. 🏌️⛳ How many patents do you think are in his bag? #patents #innovation #IP #intellectualproperty #Masters2026 #RoryMcIlroy #golf

China had 947 GLP-1 clinical trials in 2025. The US had 1,034. For a market most Western pharma teams still treat as secondary, that's a striking number. And it's not being driven by generics alone.💊 Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Hangzhou Sciwind, and PegBio Co., Ltd., already have approved GLP-1 assets. Huadong Medicine Co., Ltd., Innovent Biologics, and Tonghua Dongbao Pharmaceutical Co., Ltd., are deep in advanced clinical stages. Global pharma has taken notice. AstraZeneca paid $185M upfront to license ECC5004 out of China. Amgen brought MariTide into Chinese trials to lock in a first-in-class position. With semaglutide patents already expiring in China and India, the generics wave has started. The companies investing in next-generation assets right now are positioning for what comes after it. APAC isn't the next frontier for GLP-1 innovation. It already is one. 🌎 Our 2026 GLP-1R Market Landscape Report covers the full picture. Download here: https://bit.ly/4eisEJq #GLP1 #GLP #Ozempic #NovoNordisk #Innovation #Science #DrugDevelopment #DrugDiscovery

Everyone knows GLP-1 drugs are changing medicine. But fewer people are talking about what's actually powering the race behind the scenes. 👩🔬 It's called fast-follow innovation. Companies analyze existing molecules, patents, and clinical data, then move quickly to improve on what works. Pfizer's early small-molecule research may have ended, but it sparked a wave of next-generation candidates now driving programs at AstraZeneca, Merck, and Hansoh. Our latest report gives you the full picture. 🔬 Download for free: https://bit.ly/4vg0DbH #GLP1 #Ozempic #Innovation #DrugDiscovery #GLP

At the start of 2025, Ozempic was winning FDA approvals for CKD. 💊 By December, the first global GLP-1 obesity guideline had dropped, oral small molecules were posting Phase 2b wins, and Pfizer had quietly walked away from a space it spent years trying to crack. A lot happened in between. We mapped the key milestones in the timeline below. 👇 Deals that reshaped the competitive landscape. Clinical readouts that changed what best-in-class looks like. Patent battles, new entrants, and a generics race that's already started. Want to go deeper? Our 2026 GLP-1R Trend Report gets into the competitive moves, patent expiries, pipeline shifts, and what's coming next. Free to download, link in comments. 🧠 #GLP1 #Ozempic #Innovation #DrugDiscovery #GLP

We're live at BIO Spring in Lisbon 🇵🇹 Our team Carman Yeung, Albi Gruda, Kyle Barretto, Indy Sneyd, Fraser Ghai, Lawrence Bradbury, Harry McMahon are at Booth 2A (Hall 2), showing how Patsnap's purpose-built AI agents are helping biotech and pharma teams cut through the noise. Whether that’s mapping the latest breakthroughs in drug discovery, identifying whitespace in therapeutic areas, or understanding exactly where the competitive landscape is heading. Stop by to meet the team and see how. 🧬 #BIOSpring #LifeSciences #DrugDiscovery #Biologics #IPIntelligence #Innovation #Pharma #RandD #Patsnap

💡 AI has already changed the way we approach research and development. Teams using it can scan millions of patents, uncover hidden patterns, and identify white space in a fraction of the time it would take an unassisted human researcher. But can AI actually create something innovative on its own? It’s an interesting philosophical debate, and the answer may reshape how R&D teams define their competitive edge over the next decade. 🔗 Read the full article: https://bit.ly/4sT9j5R #AIInnovation #ResearchandDevelopment #TechStrategy #FutureOfWork